Standard BioTools: Outlook Still Murky

2025-12-28 09:02:58 ET

Shares of life sciences instrument concern Standard BioTools Inc. ( LAB ) have rallied some 20% since its 3Q25 financial report on November 4, 2025, while it awaits the close of its SomaScan sale in 1H26. The prime reason for the rally has been buying from life sciences investment firm Casdin Capital, which has purchased nearly 11.2 million shares since November 7, 2025, raising its stake to 25%. With the market valuing Standard (post-divestiture) below projected balance sheet cash before Casdin's spree, that investment into an essentially blank-check company merited a deeper dive. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: